Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moderna mRNA-1273 vaccine + casirivimab + imdevimab
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intravenous, Subcutaneous
01
Overview
This therapeutic regimen involves the co-administration of the Moderna mRNA-1273 vaccine (Spikevax) and Regeneron's monoclonal antibody cocktail, casirivimab and imdevimab (REGEN-COV). mRNA-1273 is a lipid nanoparticle-encapsulated messenger RNA vaccine that encodes the prefusion-stabilized spike (S) protein of SARS-CoV-2, designed to induce both humoral and cellular immune responses. Casirivimab and imdevimab are two non-competing human IgG1 monoclonal antibodies that bind to distinct, non-overlapping epitopes on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, thereby neutralizing the virus and preventing its entry into host cells. This combination was specifically evaluated in a Phase 2 clinical trial (NCT04852978) to assess the potential interference of the monoclonal antibodies with the vaccine-induced immune response in healthy, seronegative adults.
- Brand names
- SpikevaxREGEN-COV
- Other names
- Moderna COVID-19 VaccineElasomeranCasirivimab and ImdevimabRonapreve
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Moderna mRNA-1273 vaccine + casirivimab + imdevimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moderna mRNA-1273 vaccine + casirivimab + imdevimab.